Ocugen touts COVID-19 vaccine preclinical results
Ocugen is highlighting clinical study results that show that the Covaxin COVID-19 vaccine from Bharat Biotech of India is effective against the SARS-CoV-2 Brazil variant, B.1.128.2. Read More
Novavax expands COVID-19 vaccine trial to include adolescents
Novavax has started a pediatric expansion of its phase III clinical trial for NVX-CoV2373, the company's recombinant protein vaccine candidate against COVID-19. Read More
Affinia secures $110M to move gene therapies to clinic
Affinia Therapeutics has closed $110 million in financing to further develop its proprietary gene therapy platform, to advance its programs to the clinic, and for general corporate purposes. Read More
How one cell transplant platform is poised to tackle complex diseases
Lineage Cell Therapeutics CEO Brian Culley discusses the company's cell therapy technology with ScienceBoard.net. The technology involves the transplantation of differentiated stem cells as part of an off-the-shelf allogeneic cell therapy. Read More
Clene issued 2 patents for nanocrystal platform tech
Clene has announced that the U.S. Patent and Trademark Office has issued notices of allowance for two patent applications covering device and process claims for its platform technology and advanced stage clean-surfaced nanocrystal therapeutic candidates. Read More
Qiagen introduces EZ2 Connect platform
Qiagen has announced the upcoming launch of the EZ2 Connect product line, an automated sample-processing platform that aims to benefit biomedical research, forensics, and clinical diagnostics. Read More
Thermo Fisher announces Q1 revenue increase
Thermo Fisher Scientific said that its efforts to help scale vaccine production and support diagnostic testing globally during the COVID-19 pandemic were partially responsible for significant revenue growth in its first quarter of 2021. Read More
Bio-Rad reports 1st quarter gains
Bio-Rad Laboratories on Thursday announced financial results for its first quarter. Read More
Capricor licenses exosome platform tech from Johns Hopkins
Biotech company Capricor Therapeutics announced it has signed an exclusive worldwide licensing agreement with Johns Hopkins University to include engineered exosomes for vaccines and therapeutics in its exosome technology portfolio. Read More
Sirnaomics, Walvax team up on anti-influenza siRNA
Sirnaomics Biopharmaceuticals has entered into a partnership with Walvax Biotechnology for the co-development of STP702, its anti-influenza short interfering RNA therapeutic candidate. Read More
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter